Journal
MICROBES AND INFECTION
Volume 18, Issue 5, Pages 364-368Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.micinf.2016.03.005
Keywords
BCG; VPM1002; Post-exposure vaccination
Categories
Funding
- European Union [HEALTH-F3-2009-241745, HEALTH-F4-2011-280873]
- German Federal Ministry of Education and Research (Bundestninisteriurn fur Bildung and Forschung, BMBF) [03ZZ0806A]
- Singapore Ministry of Health, National Medical Research Council, Center Grant [NMRC/CG/013/2013]
Ask authors/readers for more resources
The tuberculosis vaccine BCG Delta ureC::hly is the most advanced BCG replacement candidate in phase II clinical development. Here we assess the protective capacity of the construct administered to mice as homologous prime-boost vaccine prior Mycobacterium tuberculosis infection and as post-exposure vaccine. Multiple immunization did not improve the superior protection of BCG Delta ureC::hly over BCG. Animals with sub-clinical tuberculosis were better protected when vaccinated with BCG Delta ureC::hly as compared to BCG. Our findings suggest further consideration of BCG Delta ureC::hly as post-exposure vaccine. (C) 2016 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available